AI Article Synopsis
- [F]FEDAC is a new PET tracer that targets the translocator protein (TSPO) found in the outer membrane of mitochondria, relevant in diseases like tumors and neurodegenerative disorders.
- A study involving seven participants assessed the biodistribution of [F]FEDAC using PET/CT scans, revealing that it mainly accumulates in the liver and kidneys, with minimal presence in the brain.
- The tracer demonstrated good image quality with an effective radiation dose of 3.60 mSV for a typical dosage, indicating its potential for safe use in human imaging of TSPO.
Article Abstract
Purpose: N-benzyl-N-methyl-2-[7, 8-dihydro-7-(2-[F] fluoroethyl) -8-oxo-2-phenyl-9H-purin-9-yl] acetamide ([F] FEDAC) is a novel positron emission tomography (PET) tracer that targets the translocator protein (TSPO; 18 kDa) in the mitochondrial outer membrane, which is known to be upregulated in various diseases such as malignant tumors, neurodegenerative diseases, and neuroinflammation. This study presents the first attempt to use [F]FEDAC PET/CT and evaluate its biodistribution as well as the systemic radiation exposure to the radiotracer in humans.
Materials And Methods: Seventeen whole-body [F]FEDAC PET/CT (injected dose, 209.1 ± 6.2 MBq) scans with a dynamic scan of the upper abdomen were performed in seven participants. Volumes of interest were assigned to each organ, and a time-activity curve was created to evaluate the biodistribution of the radiotracer. The effective dose was calculated using IDAC-Dose 2.1.
Results: Immediately after the intravenous injection, the radiotracer accumulated significantly in the liver and was subsequently excreted into the gastrointestinal tract through the biliary tract. It also showed high levels of accumulation in the kidneys, but showed minimal migration to the urinary bladder. Thus, the liver was the principal organ that eliminated [F] FEDAC. Accumulation in the normal brain tissue was minimal. The effective dose estimated from biodistribution in humans was 19.47 ± 1.08 µSv/MBq, and was 3.60 mSV for 185 MBq dose.
Conclusion: [F]FEDAC PET/CT provided adequate image quality at an acceptable effective dose with no adverse effects. Therefore, [F]FEDAC may be useful in human TSPO-PET imaging.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954948 | PMC |
| http://dx.doi.org/10.1007/s12149-023-01895-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A first-in-man study of [F] FEDAC: a novel PET tracer for the 18-kDa translocator protein.
Ann Nucl Med
April 2024
Department of Radiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Article Synopsis
- [F]FEDAC is a new PET tracer that targets the translocator protein (TSPO) found in the outer membrane of mitochondria, relevant in diseases like tumors and neurodegenerative disorders.
- A study involving seven participants assessed the biodistribution of [F]FEDAC using PET/CT scans, revealing that it mainly accumulates in the liver and kidneys, with minimal presence in the brain.
- The tracer demonstrated good image quality with an effective radiation dose of 3.60 mSV for a typical dosage, indicating its potential for safe use in human imaging of TSPO.
Translocator protein imaging with F-FEDAC-positron emission tomography in rabbit atherosclerosis and its presence in human coronary vulnerable plaques.
Atherosclerosis
October 2021
Department of Pathology, Faculty of Medicine, University of Miyazaki, 889-1692, 5200, Kihara, Kiyotake, Miyazaki City, Miyazaki, Japan.
Background And Aims: This study aimed to investigate whether N-benzyl-N-methyl-2-[7,8-dihydro-7-(2-[F]fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide (F-FEDAC), a probe for translocator protein (TSPO), can visualize atherosclerotic lesions in rabbits and whether TSPO is localized in human coronary plaques.
Methods: F-FEDAC-PET of a rabbit model of atherosclerosis induced by a 0.5% cholesterol diet and balloon injury of the left carotid artery (n = 7) was performed eight weeks after the injury.
[F]FEDAC translocator protein positron emission tomography-computed tomography for early detection of mitochondrial dysfunction secondary to myocardial ischemia.
Ann Nucl Med
August 2021
Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Background: This study aimed to evaluate the biodistribution and kinetics of [F]FEDAC targeting the translocator protein TSPO in the myocardium, and to explore its use for the identification of mitochondrial dysfunction. We also assessed the feasibility of [18F]FEDAC for the early detection of mitochondrial dysfunction associated with myocardial ischemia (MI).
Methods: The radiochemical purity and stability of [F]FEDAC were analyzed by radio-high-performance liquid chromatography (radio-HPLC).
Radiosynthesis of F-fluoroethylated tracers via a simplified one-pot F-fluoroethylation method using [F]fluoroethyl tosylate.
Appl Radiat Isot
March 2021
Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, 263-855, Japan.
Recently, a straightforward one-pot method for F-fluoroethylation without azeotropic drying of cyclotron-produced [F]F was developed. In this study, we have attempted to simplify the automated radiosynthesis of two [F]fluoroethylated tracers, [F]FEDAC and [F]FET, using a desmethyl labeling precursor and [F]fluoroethyl tosylate, based on the above-mentioned method. The radiochemical yields of [F]FEDAC and [F]FET were 26 ± 3.
View Article and Find Full Text PDFIn vivo monitoring of remnant undifferentiated neural cells following human induced pluripotent stem cell-derived neural stem/progenitor cells transplantation.
Stem Cells Transl Med
April 2020
Department of Physiology, Keio University School of Medicine, Tokyo, Japan.
Transplantation of human-induced pluripotent stem cell-derived neural stem/progenitor cells (hiPSC-NS/PCs) is a promising treatment for a variety of neuropathological conditions. Although previous reports have indicated the effectiveness of hiPSC-NS/PCs transplantation into the injured spinal cord of rodents and nonhuman primates, long-term observation of hiPSC-NS/PCs post-transplantation suggested some "unsafe" differentiation-resistant properties, resulting in disordered overgrowth. These findings suggest that, even if "safe" NS/PCs are transplanted into the human central nervous system (CNS), the dynamics of cellular differentiation of stem cells should be noninvasively tracked to ensure safety.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!